Articles from Worldwide Clinical Trials

Two acclaimed subject matter experts from Worldwide Clinical Trials, a global contract research organization (CRO), will share their exclusive insights into the latest advancements in rapidly evolving GLP-1 research at the 2nd Annual GLP-1-Based Therapeutics Summit in Boston.

Worldwide Clinical Trials, a global contract research organization (CRO), has added a cutting-edge artificial intelligence (AI) tool to enhance clinical trial optimization. This new service segments patient populations to identify those most likely to drive a positive trial outcome, leading to fewer required patients per trial, reduced timelines and costs, and ultimately increased success rates for sponsors.

Jason Meggs has joined Worldwide Clinical Trials, a global contract research organization (CRO), as Chief Financial Officer (CFO) to lead its finance, accounting, and legal functions. This strategic addition positions Worldwide to drive continued above market growth, focus on innovative clinical trial solutions, and respond to rising demand in key therapeutic areas such as neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease.

Tom Zhang, PhD, Chief Scientific Officer, Large Molecule Bioanalysis, at Worldwide Clinical Trials, a global contract research organization (CRO), will present at the 16th annual Immunogenicity & Bioassay Summit.

Kellie MacLeod has joined Worldwide Clinical Trials (Worldwide), a global full-service contract research organization (CRO), as Executive Vice President, Global Quality Assurance, bringing over 23 years of extensive experience in clinical trials, quality assurance, and regulatory affairs. In this role, MacLeod will lead Worldwide’s global Quality Assurance team, setting direction and oversight for the CRO’s quality and compliance programs.

Tracey Marantal has joined Worldwide Clinical Trials, a global full-service contract research organization (CRO), as President of the Oncology Business Unit. With over two decades of clinical operations, sponsor, and supplier experience, including more than 15 years dedicated to oncology, Marantal brings a wealth of knowledge and expertise to lead the organization’s oncology portfolio which has experienced accelerated growth during a pivotal time in cancer research.

Alessandra Vignola has joined Worldwide Clinical Trials (Worldwide), a global full-service contract research organization (CRO), as President of the Cardiovascular & Metabolic Business Unit. Vignola brings more than 30 years of extensive experience in the pharmaceutical and clinical research industry, enhancing the company's leadership in these critical therapeutic areas.

Worldwide Clinical Trials (Worldwide), a global, full-service contract research organization (CRO), has been recognized in a variety of areas for its Phase II/III clinical research services in the 2024 Industry Standard Research (ISR) Benchmarking Report. ISR’s web-based, quantitative survey was conducted in Q4 2023 and included responses from 232 key decision-makers for Phase II/III CRO services from small, midsize, and large biopharma companies. View the full report here.

Worldwide Clinical Trials (Worldwide), a global full-service contract research organization (CRO), has forged a groundbreaking partnership with Centrum Badan Klinicznych PI-House, a prominent Polish clinical research site, and the Polish Psychedelic Society (PTP). This tripartite alliance was based on Poland's first industry-sponsored psychedelic study supported by Worldwide and sets the foundation for further expansion of psychedelic research in Poland. The unique collaboration was unveiled at the second edition of the biannual "Nauka Psychodeliczna" conference at the University of Warsaw. The event was hosted by PTP and the Polish Drug Policy Network, in partnership with the Faculty of Law and Administration.

Worldwide Clinical Trials (Worldwide) a leading global, full-service contract research organization (CRO), has expanded the pharmacy at its Clinical Pharmacology Unit (CPU) in San Antonio, Texas. Completed in January 2024, the expanded pharmacy provides Worldwide’s customers with streamlined processes, as well as decreased timelines and costs. Key focus areas of the project were equipment upgrades, operational demand, workplace demand, and employee engagement, with an overall goal to enhance the customer experience.

Worldwide Clinical Trials (Worldwide), a global full-service contract research organization (CRO), proudly announces results of the 2024 Industry Standard Research (ISR) Phase I CRO Benchmarking Report. The findings confirm the importance of CRO partnerships and reinforce Worldwide’s status as a top-performing CRO for Phase I services. View the full report here.

Worldwide Clinical Trials, a leading global full-service contract research organization (CRO), has released results of a recent industry survey. The report examines changing perceptions about large and midsize CROs within the pharmaceutical and biotech sectors. Derived from a diverse respondent base of clinical trial sponsors—including emerging, small, midsize, and large companies in the United States and Europe1—the findings unveil concerns about the impact of complicated market dynamics on large CRO performance and service delivery.

Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has been recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines. This marks the 11th consecutive year that Worldwide is rated as a high-performing CRO based on direct survey feedback from pharmaceutical and biotech professionals, with this year’s distinction augmented by additional honors as a Champion in several pivotal categories.

Worldwide Clinical Trials, a leading global, full-service contract research organization (CRO), has announced its Early Phase Clinical Pharmacology Unit (CPU) has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, the clinic passed a rigorous evaluation process that involved an in-depth inspection of its clinical laboratory facilities, equipment, processes, quality control measures, and personnel qualifications – conducted onsite by CAP inspectors.

Worldwide Clinical Trials (“Worldwide”), a privately held, leading global, full-service contract research organization (“CRO”), has announced the closing of its previously announced recapitalization that gives funds managed by Kohlberg & Company, LLC (“Kohlberg”), a leading private equity firm with over 35 years of experience partnering with management and companies like Worldwide, a majority stake in the company. Middle-market private equity firm TJC, which has been Worldwide’s sole investor since 2007, retains a meaningful minority equity stake in the CRO.

Worldwide Clinical Trials (“Worldwide” or the “Company”), a global, full service contract research organization (CRO) and an affiliate company of TJC, L.P. (“TJC”), announced today that an affiliate of Kohlberg & Company, LLC (“Kohlberg”), a leading private equity firm with over 35 years of experience partnering with management and companies like Worldwide, has entered into a definitive agreement to acquire the Company, in partnership with the Company’s management team. Following the sale to Kohlberg, TJC will retain a meaningful minority equity stake in the Company.

Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has appointed Jayaprakash (JP) Kotha, MBBS, Ph.D, ASCP (SH), as Vice President, Bioanalytical. Kotha now leads lab operations and all activities in Worldwide’s Bioanalytical Center of Excellence, located in Austin, Texas.

Worldwide Clinical Trials (Worldwide), the industry’s leading global, full-service contract research organization (CRO), has partnered with Every Cure, a nonprofit organization that unlocks new, often undiscovered uses for existing approved drugs by leveraging data, artificial intelligence (AI), and efficient clinical trials.

In response to the growing and ever-changing clinical research landscape and the need to bring innovative treatments to patients faster, Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has expanded its Site Alliance Collaboration with new partners across the United States and Europe. Additions include new relationships with NEXT Oncology in Spain and the pan-European Pratia Research Platform, along with its oncology research units – supported by a dedicated Global Site Alliances role, established at Worldwide last year.

Worldwide Clinical Trials (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), has announced the appointment of Barry Lederman as Chief Financial Officer (CFO) to lead its finance, accounting, and legal functions. This addition comes as Worldwide continues to scale up to meet demand and industry growth aligned with its services, customized approach, and expertise in the core therapeutic areas of cardiovascular, metabolic, neuroscience, oncology, and rare disease.

Worldwide Clinical Trials (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), has announced the appointment of Pete Duprat as Senior Vice President, Commercial, Early Phase. Duprat will lead business development and commercial activities for the CRO’s Early Phase business unit, consisting of its Bioanalytical Center of Excellence in Austin, Texas, and Clinical Pharmacology Unit in San Antonio, Texas.

Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), today announced its new SafetyVigilance™ online pharmacovigilance notification portal, hosted by InvestigatorSpace™, which drives increased speed, accuracy, and efficiency in the global distribution of safety event communications. The portal complements the organization’s already comprehensive suite of pharmacovigilance capabilities, which include a pharmacovigilance regulatory intelligence database that is unique to Worldwide.

Worldwide Clinical Trials, Inc., (Worldwide) the industry’s leading global, midsized, full-service contract research organization (CRO), and Triumph Research Intelligence (TRI), a global leader in risk-based quality management (RBQM) technology, announced they are teaming up to optimize quality for clinical trials globally.